A long road to Polypore's restoration

The potential gains are much further ahead. There are better places to put your money.

By Jim J. Jubak Nov 19, 2012 9:40PM
Dice on stock listings -- Kate Kunz/CorbisPolypore International (PPO) has staged a gradual but solid recovery from its Aug. 28 closing low at $31.39 to $37.78 Monday. Despite that 20% gain, I still decided to sell the stock out of my Jubak’s Picks portfolio on Friday. When I sold, I was still looking at a 30.5% loss since I added the stock to my portfolio on Jan. 13.

So why sell? Why not wait until the gradual upward trend reduces my losses even further?

It's never a good idea to let a desire to "get back to even" drive your investment decisions. In this case, I think the key points in making this decision should be 1) how long it would take Polypore to get back to even or better -- in other words what’s my likely return over what period if I continue to hold -- and 2) how does that compare to the potential returns I could earn from other opportunities in the current market?

I think Polypore’s Oct. 29 report of third quarter earnings supports a decision to sell. The company earned 37 cents a share, beating the Wall Street consensus by 3 cents a share. Revenue dropped, however, by 6.6% from the third quarter of 2011, although it came in, at $177.6 million, above the analyst forecast of $174.22 million.

But it’s the company’s guidance that really struck me. I’ve rarely heard such caution from a company that was still optimistic about its long-term potential. The fourth quarter will be better than the third, the company said, but management still adjusted guidance to the low end of the 50 cents to 60 cents range that it had projected earlier. (The analyst consensus for the quarter was at 56 cents a share.) 

In the company’s very important electric-vehicle market, the best the company offered was a belief that certain production facilities anticipated by its customers to start up late in the fourth quarter would indeed start up on schedule. In other words, Polypore won’t see any improvement in its revenue for separators for batteries in electric vehicles in the fourth quarter even if the projected factories do go on line. And they might not go into production as anticipated.

Other business lines got equally cautious good news. Health care customers in Italy resumed production at the end of the third quarter -- great but that’s not the same as projecting actual growth from pre-euro-debt-crisis trends. In its business of making separators for batteries in the consumer electronics market, the best the company could say was that it expected "no further weakening of the consumer electronics market due to macroeconomic factors."

Still, without the near-correction in the overall market -- the Standard & Poor's 500 Index ($INX) is
down 8.3% from the Sept. 14 high to the close on Nov. 15 -- I’d probably be willing to hold on to Polypore with great patience until the electric vehicle and consumer electronics markets recover enough to restore the company to a growth track.

But as I wrote in this post, the near-correction so far and the volatility yet to come on the euro debt crisis, uncertainty about growth rates in China, and the U.S. fiscal cliff will, during the remainder of the year, create very attractive buying opportunities in stocks that have the potential to show serious gains in the first half of 2013. In contrast, I think the potential gains in Polypore are much further down the road. Looking at continuing to own Polypore in terms of opportunity costs, I just think that there will be better places to put the money I realize from this sale to work.

At the time of this writing, Jim Jubak didn't own shares of any companies mentioned in this post in personal portfolios. The mutual fund he manages, Jubak Global Equity Fund (JUBAX), may or may not own positions in any stock mentioned. The fund did not own shares of Polypore International as of the end of September. For a full list of the stocks in the fund as of the end of the most recent quarter, see the fund's portfolio here. 
Tags: PPO


Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.


StockScouter rates stocks from 1 to 10, with 10 being the best, using a system of advanced mathematics to determine a stock's expected risk and return. Ratings are displayed on a bell curve, meaning there will be fewer ratings of 1 and 10 and far more of 4 through 7.

123 rated 1
262 rated 2
480 rated 3
651 rated 4
649 rated 5
629 rated 6
616 rated 7
496 rated 8
346 rated 9
111 rated 10

Top Picks

TAT&T Inc9



Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.

Contributors include professional investors and journalists affiliated with MSN Money.

Follow us on Twitter @topstocksmsn.